How can the recent shareholder update could possibly be driving this ramp. Full of promises, a whole pile of new trademarks and ridiculous statements like: "....the next big thing in medicine" and "...hope for the hopeless". Really?? Who writes this stuff?
Where are the deals they speak so much about? If ExoPharm's smoke and mirrors is so good why have NOT done deals like Codiak?
With 40 mouths to feed shareholders should expect another cap raise soon to drive this level of spend.
Where are the results of the first clinical trial that was quietly halted last year?
At least now they have promised the moon and stars so shareholders will be able to judge soon if this real.
EX1 Price at posting:
63.0¢ Sentiment: Sell Disclosure: Not Held
